Overview of R/R FL: Focus on the 3rd-Line Setting and Beyond START

Now Viewing

EP: 1.Overview of R/R FL: Focus on the 3rd-Line Setting and Beyond START

EP: 2.Managing 3rd-Line R/R FL: Recognizing Progression, Performing Rebiopsies, and Rechecking for CD20 Positivity

EP: 3.Aligning Treatment Goals in R/R FL: Physician vs Patient Perspectives

EP: 4.Clinical Scenario: A 73-Year-Old Patient With R/R FL Requires Treatment in the Third-Line Setting

EP: 5.Expert Perspectives: Tazemetostat in R/R FL

EP: 6.Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations

EP: 7.Assessing CAR T and Bispecifics for R/R FL: Identifying the Right Candidates & Factoring in CD20 and CD19 Negativity or Positivity

EP: 8.Navigating Treatment Choices in R/R FL: Patient Values and Shared Decision-Making

EP: 9.Managing R/R FL: Evolving Sequencing Strategies

EP: 10.Key Strategies and Perspectives: How Novel 2nd-Line Therapy Options May Impact 3rd-Line Treatment Landscape in R/R FL and Bridging Strategies to CAR T

EP: 11.Collaborating With Community Providers in Treating Patients With Complex R/R FL

EP: 12.Looking Ahead in R/R FL: Unmet Needs and What’s Next

EP: 13.Physician Assistant Perspectives: Aligning Patient Goals in R/R FL and Navigating Third-Line Treatment Options

EP: 14.Physician Assistant Perspectives: Importance of Patient Shared Decision-Making and Multidisciplinary Team Approach in R/R FL

EP: 15.Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FL

Summary for Physicians:

Topic: Overview of R/R FL and Third-Line Treatment Considerations

Key Points:

1. Disease Overview and Heterogeneity:

• FL is generally considered an indolent, slow-growing B-cell non-Hodgkin lymphoma. Despite this, the disease course can be highly heterogeneous—some patients may remain stable for years, while others experience more rapid progression or transformation into aggressive lymphoma.

• The management of R/R FL requires balancing the typically indolent nature of the disease with the need for timely intervention when progression occurs.

1. Timing and Need for Third-Line Therapy:

• The need for third-line treatment typically arises when patients relapse following their second-line therapy. The time to progression can vary significantly among individuals.

• Some patients may progress within a short period after second-line therapy (particularly those with early progression within 24 months, or POD24), which is associated with a poorer prognosis and may necessitate more aggressive treatment approaches.

• Others may have prolonged responses before requiring third-line intervention.

1. Clinical Indicators of Progression:

• Common signs and symptoms indicating progression of disease include the following:

• Increasing lymphadenopathy (new or enlarging lymph nodes)

• B symptoms (fever, night sweats, weight loss)

• Cytopenias or declining performance status

• Radiologic or laboratory evidence of disease progression

• Monitoring for these indicators is critical in determining when to initiate third-line treatment and tailoring it to the patient’s clinical status and prior treatment history.

Clinical Implications: Physicians treating patients with R/R FL should remain vigilant for signs of progression, especially in those with early relapse or high-risk features. Given the variability in disease course, individualized treatment strategies and timely intervention in the third-line setting are essential for optimizing outcomes.